Sanofi’s bispecific scores in respiratory diseases but fails in eczema
Sanofi’s lunsekimig met its endpoints in asthma and CRSwNP but missed the primary endpoint in eczema.
08 April 2026
08 April 2026
Sanofi’s lunsekimig met its endpoints in asthma and CRSwNP but missed the primary endpoint in eczema.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.